Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 18/20 | 0.70 |
| ▸ | MTNR1B | P49286 | 16/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1566620 | 0.93 | MTNR1A (0.66) | MTNR1AMTNR1B | |
| SCHEMBL4690876 | 0.91 | MTNR1A (0.80) | MTNR1AMTNR1B | |
| SCHEMBL1566624 | 0.82 | MTNR1A (0.55) | MTNR1AMTNR1BSIGMAR1 | |
| Hydrochloric Acid SCHEMBL4691174 | 0.78 | MTNR1A (0.52) | MTNR1AMTNR1B | |
| SCHEMBL1566409 | 0.75 | MTNR1B (0.79) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL4685349 | 0.74 | MTNR1A (0.47) | MTNR1AMTNR1B | |
| SCHEMBL1566525 | 0.69 | MTNR1A (0.76) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL124090 | 0.69 | MTNR1B (0.82) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL2881136 | 0.68 | MTNR1B (0.56) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL793401 | 0.68 | MTNR1B (0.56) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306167-A1 | Pharmaceutical Compositions for Intranasal Administration Comprising a Melatonin Receptor Agonist, Uses Thereof | INTRANASAL THERAPEUTICS, INC. | 2009-12-10 | — | — | US | claimed |
| CN-100443480-C | Tricyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2008-12-17 | — | — | CN | claimed |
| EP-0885210-B2 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA PHARMACEUTICAL (JP) | 2008-06-18 | — | — | EP | claimed |
| CN-1900067-A | Tricyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2007-01-24 | — | — | CN | claimed |
| CN-1727339-A | Tricyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-01 | — | — | CN | claimed |
| EP-0885210-B1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | EP | claimed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | claimed |
| CN-1212691-A | Tricyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-03-31 | — | — | CN | claimed |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20170128409-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-26 | — | — | US | disclosed |
| CN-101983193-B | Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder | TAKEDA PHARMACEUTICAL | 2014-03-12 | — | — | CN | disclosed |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | SUZUKI YASUYUKI (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8183285-B2 | Therapeutic agent for irritable bowel syndrome and methods thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-1199304-A1 | Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders | Takeda Chemical Industries, Ltd. (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6218429-B1 | TREATING MELATONIN RELATED DISORDERS (E.G. CIRCARDIAN RHYTHMS, SLEEP-AWAKE CYCLES, TIME ZONE CHANGES, SLEEP DISORDERS) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| CN-1212691-A | Tricyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-03-31 | — | — | CN | disclosed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | PRCP, COPS6, COPS5 | MTNR1A 3487/4885MTNR1B 3104/4885ABCB11 108/4885 |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | MTNR1A 3487/4885MTNR1B 3104/4885ABCB11 108/4885 |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | MTNR1A, MTNR1B, MC1R | MTNR1A 1/4885MTNR1B 2/4885ABCB11 148/4885 |
| US-20090306167-A1 | Pharmaceutical Compositions for Intranasal Administration Comprising a Melatonin Receptor Agonist, Uses Thereof | MTNR1A, MTNR1B, MCHR1 | MTNR1A 1/4885MTNR1B 2/4885ABCB11 2508/4885 |
| US-20170128409-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | AANAT, DBH, CHAT | MTNR1A 99/4885MTNR1B 56/4885ABCB11 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.